Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Lysarc
Sponsor

Lysarc

France 2d Lyon Sud Batiment, 69495 Pierre Benite, France

About the sponsor

Research activity includes diffuse large B-cell lymphoma, relapsed/refractory aggressive B-NHL, primary diffuse large B-cell lymphoma of the CNS, and other high-risk B-cell malignancies, with interest in both newly diagnosed and relapsed settings.

  • CAR T-cell therapy
  • Bispecific antibodies
  • Anti-CD19 and anti-CD20 approaches
  • Lenalidomide-based combinations

Additional work spans molecular response, complete response, and progression-free survival in aggressive lymphoma subtypes.

About Specializations

Lysarc runs clinical trials in conditions such as Diffuse large B-cell lymphoma, Peripheral T-cell lymphoma unspecified, Mantle cell lymphoma, B-cell lymphoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

16 clinical trials

Peripheral T-cell lymphoma unspecified+1

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Lysarc

Central nervous system lymphoma+1

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Lysarc

Mantle cell lymphoma

Recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Lysarc

B-cell lymphoma+1

Recruiting
InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Valemetostat Tosilate
  • Sponsor:Lysarc

Diffuse large B-cell lymphoma

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Golcadomide
  • Sponsor:Lysarc

Peripheral T-cell lymphoma unspecified

Recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin
  • Sponsor:Lysarc

Marginal zone lymphoma refractory

Recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Lysarc

Diffuse large B-cell lymphoma

Not yet recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Lysarc

Angioimmunoblastic T-cell lymphoma refractory

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Lysarc

Peripheral T-cell lymphoma unspecified

Not recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Lysarc

Diffuse large B-cell lymphoma+1

Not recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Lysarc

Follicular lymphoma

Not recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Lysarc

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.